Novartis AG Operating Income 2006-2018 | NVS

Novartis AG annual/quarterly operating income history and growth rate from 2006 to 2018. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Novartis AG operating income for the quarter ending December 31, 2018 was $1.299B, a 37.25% decline year-over-year.
  • Novartis AG operating income for the twelve months ending December 31, 2018 was $8.169B, a 5.33% decline year-over-year.
  • Novartis AG annual operating income for 2018 was $8.169B, a 5.33% decline from 2017.
  • Novartis AG annual operating income for 2017 was $8.629B, a 4.37% increase from 2016.
  • Novartis AG annual operating income for 2016 was $8.268B, a 7.9% decline from 2015.
Novartis AG Annual Operating Income
(Millions of US $)
2018 $8,169
2017 $8,629
2016 $8,268
2015 $8,977
2014 $11,089
2013 $10,983
2012 $11,507
2011 $10,780
2010 $11,526
2009 $9,982
2008 $8,964
2007 $6,781
2006 $7,642
2005 $6,507
Novartis AG Quarterly Operating Income
(Millions of US $)
Q4 2018 $1,299
Q3 2018 $1,939
Q2 2018 $2,484
Q1 2018 $2,447
Q4 2017 $2,070
Q3 2017 $2,357
Q2 2017 $2,280
Q1 2017 $1,922
Q4 2016 $1,455
Q3 2016 $2,269
Q2 2016 $2,093
Q1 2016 $2,451
Q4 2015 $1,677
Q3 2015 $2,234
Q2 2015 $2,281
Q1 2015 $2,785
Q4 2014 $2,351
Q3 2014 $2,739
Q2 2014 $3,184
Q1 2014 $2,815
Q4 2013 $2,496
Q3 2013 $2,558
Q2 2013 $3,033
Q1 2013 $2,896
Q4 2012 $2,715
Q3 2012 $2,948
Q2 2012 $3,108
Q1 2012 $2,736
Q4 2011 $1,099
Q3 2011 $2,951
Q2 2011 $3,322
Q1 2011 $3,408
Q4 2010 $2,467
Q3 2010 $2,587
Q2 2010 $2,961
Q1 2010 $3,511
Q4 2009 $2,637
Q3 2009 $2,634
Q2 2009 $2,364
Q1 2009 $2,347
Q4 2008 $1,680
Q3 2008 $2,335
Q2 2008 $2,461
Q1 2008 $2,488
Q4 2007 $897
Q3 2007 $1,452
Q2 2007 $2,097
Q1 2007 $2,335
Q4 2006 $1,641
Q3 2006 $1,979
Q2 2006 $1,964
Q1 2006 $2,058
Q4 2005 $1,090
Q3 2005 $1,888
Q2 2005 $1,849
Q1 2005 $1,680
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $175.329B $51.900B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $375.338B 17.02
Pfizer (PFE) United States $234.662B 13.14
Merck (MRK) United States $201.136B 17.19
Eli Lilly (LLY) United States $121.698B 21.13
Novo Nordisk (NVO) Denmark $118.902B 19.23
AbbVie (ABBV) United States $116.030B 9.94
Sanofi (SNY) France $104.612B 12.91
GlaxoSmithKline (GSK) United Kingdom $99.770B 13.10
AstraZeneca (AZN) United Kingdom $97.998B 11.18
Bristol-Myers Squibb (BMY) United States $74.051B 11.39